AbCellera to announce Phase 2 top-line results for ABCL635
AbCellera Biologics will release Phase 2 trial data for ABCL635 on Monday, August 10, 2026. This potential first-in-class antibody for menopause symptoms is expected to drive investor attention and market speculation regarding the company's pipeline valuations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day